We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Amarin (AMRN) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Amarin (AMRN - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Amarin is a member of the Medical sector. This group includes 988 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Amarin is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for AMRN's full-year earnings has moved 54.1% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, AMRN has returned 73.3% so far this year. At the same time, Medical stocks have lost an average of 2.7%. This shows that Amarin is outperforming its peers so far this year.
Abbott (ABT - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 20.5%.
In Abbott's case, the consensus EPS estimate for the current year increased 0.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Amarin belongs to the Medical - Biomedical and Genetics industry, a group that includes 496 individual stocks and currently sits at #86 in the Zacks Industry Rank. This group has lost an average of 2.2% so far this year, so AMRN is performing better in this area.
In contrast, Abbott falls under the Medical - Products industry. Currently, this industry has 84 stocks and is ranked #151. Since the beginning of the year, the industry has moved +7.6%.
Amarin and Abbott could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Amarin (AMRN) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Amarin (AMRN - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Amarin is a member of the Medical sector. This group includes 988 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Amarin is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for AMRN's full-year earnings has moved 54.1% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, AMRN has returned 73.3% so far this year. At the same time, Medical stocks have lost an average of 2.7%. This shows that Amarin is outperforming its peers so far this year.
Abbott (ABT - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 20.5%.
In Abbott's case, the consensus EPS estimate for the current year increased 0.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Amarin belongs to the Medical - Biomedical and Genetics industry, a group that includes 496 individual stocks and currently sits at #86 in the Zacks Industry Rank. This group has lost an average of 2.2% so far this year, so AMRN is performing better in this area.
In contrast, Abbott falls under the Medical - Products industry. Currently, this industry has 84 stocks and is ranked #151. Since the beginning of the year, the industry has moved +7.6%.
Amarin and Abbott could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.